clinical data analysis News
-
Application of Whole-Genome Sequencing in Older Esophageal Carcinoma FFPE Tissues Reveals Novel Insights
Collection of fresh-frozen tumor samples is often challenging or infeasible, leading many studies to rely on formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Because these tissues are often paired with a great deal of clinical and outcome data, analysis of these archives has the potential to lead to major advances in cancer treatment and prevention. Whole-genome sequencing (WGS) ...
-
Prognos Health and xCures Partner to enable Access to Real World Oncology Datasets
Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access and insights for life science companies across multiple use cases. The multi-year agreement will enable linking and access to xCures de-identified data and Prognos healthcare data marketplace. “We are excited about combining ...
By xCures
-
GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer
The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the completion of its Piedmont ...
-
New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations
/www.w3.org/1999/xhtml">New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations Novartis International AG / New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations . Processed and transmitted by Thomson ...
-
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia will receive an upfront cash payment of $100 ...
By Exscientia
-
Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
/www.w3.org/1999/xhtml">Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer Novartis International AG / Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of ...
-
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
/www.w3.org/1999/xhtml">Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no ...
-
OncoDNA Announces the Operational Launch of its OncoDEEP Kit for Comprehensive Genomic Profiling of Solid Tumors
A UNIQUE WORKFLOW SOLUTION INTEGRATING A PAN-CANCER NEXT-GENERATION SEQUENCING (NGS) PANEL POWERED BY A BIOINFORMATICS SOFTWARE SUITE FOR CUSTOMIZABLE BIOLOGICAL AND CLINICAL INTERPRETATION ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, TODAY ANNOUNCED THE OFFICIAL LAUNCH OF THE ONCODEEP KIT DURING THE ESMO ...
By OncoDNA S.A.
-
OncoDNA Launches OncoDEEP® Kit for Comprehensive Biomarker Testing of Solid Tumors
UNIQUE WORKFLOW SOLUTION INTEGRATING A COMPRENSIVE PAN-CANCER NGS PANEL POWERED BY TWIST BIOSCIENCE AND A BIOINFORMATICS SOFTWARE SUITE ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY THE LAUNCH OF THE ONCODEEP KIT. THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION WHICH ENABLES LABORATORIES WITH NGS ...
By OncoDNA S.A.
-
New Data Demonstrates Substantial Reduction of Migraine Days Using Neurolief’s Digital Therapeutics Technology
Neurolief, a neurotechnology innovator, today announced new data released at the 64th Annual Scientific Meeting hosted by the American Headache Society (June 9-12th, 2022, Denver, CO). The real-world, open-label analysis presents clinically meaningful data on the prevention of migraine, including responder rate, reduction in monthly migraine days and reduction in medication use for those with ...
-
VIDA Introduces New AI-Enabled Biomarker Services
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. Announced at the 2022 American Thoracic Society (ATS) International Conference, this suite of services empowers sponsors to leverage ...
-
Second Heart Assist Announces Successful Completion of Long-Duration Pre-Clinical Studies
NEWS PROVIDED BY Second Heart Assist, Inc. June 22nd, 2020 7:00am ET Salt Lake City, Utah, June 22nd, 2020 /PRDistribution/ — Second Heart Assist Inc., inventors of the first, true, aortic stent-based circulatory assist pump intended primarily for use in heart failure patients, announces the successful completion of a series of long-duration preclinical studies in pulsatile mock loop and ...
-
Cardiac Dimensions Announces Two New Meta-Analysis Publications Showing Statistically Significant and Clinically Meaningful Benefits to Heart Failure Patients Suffering from Functional Mitral Regurgitation
Cardiac Dimensions announced a published second individual patient data meta-analysis demonstrating clinically significant outcomes for the Carillon Mitral Contour System®. This publication, in addition to the several others recently published on the Carillon device, continues the series of excellent results for this transcatheter-based indirect annuloplasty device. Both of the published ...
-
Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 weeks at week 48
Aflibercept 8 mg demonstrated non-inferior vision gains to Eylea® (aflibercept 2 mg) with 83% of patients with neovascular (wet) age-related macular degeneration (nAMD) and 93% of patients with diabetic macular edema (DME) maintaining dosing intervals of 12 weeks or longer through week 48 Superior fluid control in nAMD and robust disease control through to week 48 in nAMD and DME In both ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you